Insulin-like growth factor 2 silencing restores taxol sensitivity in drug resistant ovarian cancer

PLoS ONE

Volumn 9, Issue 6, 2014, Pages

  Brouwer Visser, Jurriaan ^a   Lee, Jiyeon ^a   McCullagh, KellyAnne ^a   Cossio, Maria J ^a   Wang, Yanhua ^a   Huang, Gloria S ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CIXUTUMUMAB; DOXORUBICIN; IXABEPILONE; MULTIDRUG RESISTANCE PROTEIN 1; NVP AEW 541; OREGON GREEN 488; PACLITAXEL; SOMATOMEDIN B; UNCLASSIFIED DRUG; VERAPAMIL; VINBLASTINE; ANTINEOPLASTIC AGENT; IGF2 PROTEIN, HUMAN; MESSENGER RNA; SMALL INTERFERING RNA; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER MORTALITY; CANCER SURVIVAL; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DRUG SENSITIVITY; FEMALE; G2 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION; IC 50; IN VIVO STUDY; LOW DRUG DOSE; MOUSE; NONHUMAN; OVARIAN CANCER CELL LINE; OVARY CANCER; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; TREATMENT RESPONSE; TUMOR GROWTH; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL CYCLE; CYSTADENOCARCINOMA, SEROUS; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; GENETICS; HUMAN; METABOLISM; NUDE MOUSE; OVARIAN NEOPLASMS; PATHOLOGY; PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR CELL CULTURE; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BLOTTING, WESTERN; CELL CYCLE; CELL PROLIFERATION; CYSTADENOCARCINOMA, SEROUS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; INSULIN-LIKE GROWTH FACTOR II; MICE; MICE, NUDE; OVARIAN NEOPLASMS; PACLITAXEL; PHOSPHORYLATION; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR, IGF TYPE 1; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84903217604     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0100165     Document Type: Article

References (34)

1. Vaughan S, Coward JI, Bast RC, Berchuck A, Berek JS, et al. (2011) Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer 11: 719-725. doi:10.1038/nrc3144.
2. Ratajczak MZ, Shin D-M, Schneider G, Ratajczak J, Kucia M (2013) Parental imprinting regulates insulin-like growth factor signaling: a Rosetta Stone for understanding the biology of pluripotent stem cells, aging and cancerogenesis. Leukemia 27: 773-779. doi:10.1038/leu.2012.322.
3. Baker J, Liu JP, Robertson EJ, Efstratiadis A (1993) Role of insulin-like growth factors in embryonic and postnatal growth. Cell 75: 73-82. (Pubitemid 23306022)
4. Gallagher EJ, LeRoith D (2011) Minireview: IGF, Insulin, and Cancer. Endocrinology 152: 2546-2551. doi:10.1210/en.2011-0231.
5. Pollak M (2012) The insulin and insulin-like growth factor receptor family in neoplasia: an update. Nat Rev Cancer 12: 159-169. doi:10.1038/nrc3215.
6. Tazearslan C, Huang J, Barzilai N, Suh Y (2011) Impaired IGF1R signaling in cells expressing longevity-associated human IGF1R alleles. Aging Cell 10: 551-554. doi:10.1111/j.1474-9726.2011.00697.x.
7. Huang GS, Brouwer-Visser J, Ramirez MJ, Kim CH, Hebert TM, et al. (2010) Insulin-like growth factor 2 expression modulates Taxol resistance and is a candidate biomarker for reduced disease-free survival in ovarian cancer. Clin Cancer Res 16: 2999-3010. doi:10.1158/1078-0432.CCR-09-3233.
8. Sherman-Baust CA, Becker KG, Wood Iii WH, Zhang Y, Morin PJ (2011) Gene expression and pathway analysis of ovarian cancer cells selected for resistance to cisplatin, paclitaxel, or doxorubicin. J Ovarian Res 4: 21. doi:10.1186/1757-2215-4-21.
9. Eckstein N, Servan K, Hildebrandt B, Politz A, Jonquieres GV, et al. (2009) Hyperactivation of the Insulin-like Growth Factor Receptor I Signaling Pathway Is an Essential Event for Cisplatin Resistance of Ovarian Cancer Cells. Cancer Res 69: 2996-3003. doi:10.1158/0008-5472.CAN-08-3153.
10. Gotlieb WH, Bruchim I, Gu J, Shi Y, Camirand A, et al. (2006) Insulin-like growth factor receptor I targeting in epithelial ovarian cancer. Gynecol Oncol 100: 389-396. doi:10.1016/j.ygyno.2005.09.048. (Pubitemid 43075275)
11. Ogawa T, Ogawa K, Shiga K, Furukawa T, Nagase H, et al. (2010) Upregulation of IGF2 is associated with an acquired resistance for cisdiamminedichloroplatinum in human head and neck squamous cell carcinoma. Eur Arch Otorhinolaryngol 267: 1599-1606. doi:10.1007/s00405-010-1257-4.
12. Eva A, Robbins KC, Andersen PR, Srinivasan A, Tronick SR, et al. (1982) Cellular genes analogous to retroviral onc genes are transcribed in human tumour cells. Nature 295: 116-119. (Pubitemid 12135132)
13. Buick RN, Pullano R, Trent JM (1985) Comparative properties of five human ovarian adenocarcinoma cell lines. Cancer Res 45: 3668-3676. (Pubitemid 15226443)
14. Hamilton TC, Young RC, Ozols RF (1984) Experimental model systems of ovarian cancer: applications to the design and evaluation of new treatment approaches. Semin Oncol 11: 285-298. (Pubitemid 14013135)
15. Shahabi S, Yang C-PH, Goldberg GL, Horwitz SB (2010) Epothilone B enhances surface EpCAM expression in ovarian cancer Hey cells. Gynecol Oncol 119: 345-350. doi:10.1016/j.ygyno.2010.07.005.
16. García-Echeverría C, Pearson MA, Marti A, Meyer T, Mestan J, et al. (2004) In vivo antitumor activity of NVP-AEW541-A novel, potent, and selective inhibitor of the IGF-IR kinase. Cancer Cell 5: 231-239. (Pubitemid 38402115)
17. Cancer Genome Atlas Research Network (2011) Integrated genomic analyses of ovarian carcinoma. Nature 474: 609-615. doi:10.1038/nature10166.
18. Ballester M, Castelló A, Ibáñez E, Sánchez A, Folch JM (2004) Real-time quantitative PCR-based system for determining transgene copy number in transgenic animals. BioTechniques 37: 610-613. (Pubitemid 39391178)
19. Marcelletti JF, Multani PS, Lancet JE, Baer MR, Sikic BI (2009) Leukemic blast and natural killer cell P-glycoprotein function and inhibition in a clinical trial of zosuquidar infusion in acute myeloid leukemia. Leukemia Research 33: 769-774. doi:10.1016/j.leukres.2008.09.020.
20. Duan Z, Brakora KA, Seiden MV (2004) Inhibition of ABCB1 (MDR1) and ABCB4 (MDR3) expression by small interfering RNA and reversal of paclitaxel resistance in human ovarian cancer cells. Mol Cancer Ther.
21. Stordal B, Hamon M, McEneaney V, Roche S, Gillet J-P, et al. (2012) Resistance to paclitaxel in a cisplatin-resistant ovarian cancer cell line is mediated by P-glycoprotein. PLoS ONE 7: e40717. doi:10.1371/journal.-pone. 0040717.
22. He L, Yang CP, Horwitz SB (2001) Mutations in beta-tubulin map to domains involved in regulation of microtubule stability in epothilone-resistant cell lines. Mol Cancer Ther 1: 3-10. doi:10.1038/277665a0.
23. Huang GS, Lopez-Barcons L, Freeze BS, Smith AB, Goldberg GL, et al. (2006) Potentiation of taxol efficacy and by discodermolide in ovarian carcinoma xenograft-bearing mice. Clin Cancer Res 12: 298-304. doi:10.1158/1078-0432.CCR- 05-0229. (Pubitemid 43166207)
24. Beauchamp M-C, Yasmeen A, Knafo A, Gotlieb WH (2010) Targeting insulin and insulin-like growth factor pathways in epithelial ovarian cancer. J Oncol 2010: 257058. doi:10.1155/2010/257058.
25. Greenall SA, Bentley JD, Pearce LA, Scoble JA, Sparrow LG, et al. (2013) Biochemical Characterization of Individual Human Glycosylated pro-Insulinlike Growth Factor (IGF)-II and big-IGF-II Isoforms Associated with Cancer. J Biol Chem 288: 59-68. doi:10.1074/jbc.M112.432013.
26. Ulanet DB, Ludwig DL, Kahn CR, Hanahan D (2010) Insulin receptor functionally enhances multistage tumor progression and conveys intrinsic resistance to IGF-1R targeted therapy. Proc Natl Acad Sci USA 107: 10791-10798. doi:10.1073/pnas.0914076107.
27. Wu JD, Odman A, Higgins LM, Haugk K, Vessella R, et al. (2005) In vivo effects of the human type I insulin-like growth factor receptor antibody A12 on androgen-dependent and androgen-independent xenograft human prostate tumors. Clin Cancer Res 11: 3065-3074. doi:10.1158/1078-0432.CCR-04-1586. (Pubitemid 40525213)
28. Lee AV, Darbre P, King RJB (1994) Processing of insulin-like growth factor-II (IGF-II) by human breast cancer cells. Molecular and Cellular Endocrinology 99: 211-220. doi:10.1016/0303-7207(94)90010-8.
29. Duguay SJ (1998) Post-translational Processing of the Insulin-like Growth Factor-2 Precursor. ANALYSIS OF O-GLYCOSYLATION AND ENDOPROTEOLYSIS. J Biol Chem 273: 18443-18451. doi:10.1074/jbc.273.29.18443.
30. Torres K, Horwitz SB (1998) Mechanisms of Taxol-induced cell death are concentration dependent. Cancer Res 58: 3620-3626. (Pubitemid 28376560)
31. Hope-Roberts M, Horobin RW, Wainwright M (2011) Identifying apoptotic cells with the 3-hydroxyflavone derivative F2N12S, a ratiometric fluorescent small molecule probe selective for plasma membranes: a possible general mechanism for selective uptake into apoptotic cells. Biotech Histochem 86: 255-261. doi:10.3109/10520291003723426.
32. Ulanet DB, Ludwig DL, Kahn CR, Hanahan D (2010) Insulin receptor functionally enhances multistage tumor progression and conveys intrinsic resistance to IGF-1R targeted therapy. Proc Natl Acad Sci USA 107: 10791-10798. doi:10.1073/pnas.0914076107/-/DCSupplemental.
33. Garofalo C, Manara MC, Nicoletti G, Marino MT, Lollini P-L, et al. (2011) Efficacy of and resistance to anti-IGF-1R therapies in Ewing's sarcoma is dependent on insulin receptor signaling. Oncogene 30: 2730-2740. doi:10.1038/onc.2010.640.
34. Amit D, Hochberg A (2010) Development of targeted therapy for bladder cancer mediated by a double promoter plasmid expressing diphtheria toxin under the control of H19 and IGF2-P4 regulatory sequences. J Transl Med 8: 134. doi:10.1186/1479-5876-8-134.